Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants
jRCT2080225365Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 20 in pneumococcal disease (3 arms), sponsored by Pfizer. Started Aug 2020; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on jRCT2080225365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225365.